Ultragenyx Pharmaceutical
RARE
274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
52% more call options, than puts
Call options by funds: $22.7M | Put options by funds: $15M
46% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 80
18% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 40
2% more funds holding
Funds holding: 269 → 274 (+5)
0.33% more ownership
Funds ownership: 97.06% → 97.4% (+0.33%)
3% less capital invested
Capital invested by funds: $3.73B → $3.63B (-$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$72.2M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$63.8M |
| 3 |
Millennium Management
New York
|
+$48.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$41.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$163M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24.6M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$20.5M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$16.8M |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$9.75M |
RARE Hedge Fund Activity: Q2 2024 in Review
274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.
- 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
- Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
- 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.
Based on aggregated 13F filings for Q2 2024.